These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36819192)

  • 41. Biopsy findings after detection of de novo donor-specific antibodies in renal transplant recipients: a single center experience.
    Waldecker CB; Zgoura P; Seibert FS; Gall S; Schenker P; Bauer F; Rohn B; Viebahn R; Babel N; Westhoff TH
    J Nephrol; 2021 Dec; 34(6):2017-2026. PubMed ID: 33866524
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Impact of Donor-Specific Anti-Human Leukocyte Antigen (HLA) Antibody Rebound on the Risk of Antibody Mediated Rejection in Sensitized Kidney Transplant Recipients.
    Lee KW; Park JB; Cho CW; Lee N; Yoo H; Kim K; Park H; Kang ES; Huh W; Kim S
    Ann Transplant; 2017 Mar; 22():166-176. PubMed ID: 28348361
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Terasaki Epitope Mismatch Burden Predicts the Development of De Novo DQ Donor-Specific Antibodies and are Associated With Adverse Allograft Outcomes.
    Willicombe M; Blow M; Santos-Nunez E; Freeman C; Brookes P; Taube D
    Transplantation; 2018 Jan; 102(1):127-134. PubMed ID: 28731902
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption.
    Kälble F; Süsal C; Pego da Silva L; Speer C; Benning L; Nusshag C; Pham L; Tran H; Schaier M; Sommerer C; Beimler J; Mehrabi A; Zeier M; Morath C
    Front Med (Lausanne); 2021; 8():781491. PubMed ID: 34977083
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical Outcome of Kidney Transplant Patients on the Allograft Function, Loss, Effects of HLA-DQB1-DSA
    Cunha APL; Fabreti-Oliveira RA; Lasmar MF; Garcia JC; Vilela TP; Nascimento E
    Transplant Proc; 2021 Sep; 53(7):2188-2196. PubMed ID: 34420780
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The challenge of HLA donor specific antibodies in the management of pancreatic islet transplantation: an illustrative case-series.
    Maanaoui M; Chetboun M; Top I; Elsermans V; Kerr-Conte J; Le Mapihan K; Defrance F; Gmyr V; Hubert T; Labalette M; Hazzan M; Vantyghem MC; Pattou F
    Sci Rep; 2022 Jul; 12(1):12463. PubMed ID: 35864198
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies.
    Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J
    Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Outcome of Extracorporeal Photopheresis as an Add-On Therapy for Antibody-Mediated Rejection in Lung Transplant Recipients.
    Benazzo A; Worel N; Schwarz S; Just U; Nechay A; Lambers C; Böhmig G; Fischer G; Koren D; Muraközy G; Knobler R; Klepetko W; Hoetzenecker K; Jaksch P
    Transfus Med Hemother; 2020 Jun; 47(3):205-213. PubMed ID: 32595425
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.
    Steggerda JA; Kim IK; Haas M; Zhang X; Kang A; Pizzo H; Kamil E; Jordan S; Puliyanda D
    Pediatr Transplant; 2017 Dec; 21(8):. PubMed ID: 29159992
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clearance of Intra-graft Donor Specific Anti-HLA Antibodies in the Early Stage of Antibody-Mediated Rejection Following Rituximab and Apheresis Therapy in Renal Transplantation.
    Nakamura T; Yoshimura N; Akioka K; Shirouzu T; Kawai S; Imanishi Y; Matsuyama T; Harada S; Nobori S; Ushigome H
    Transplant Proc; 2019 Jun; 51(5):1365-1370. PubMed ID: 31056246
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after heart transplantation.
    Omrani O; Alawwami M; Buraiki J; Selimovic N
    Ann Saudi Med; 2018; 38(2):97-104. PubMed ID: 29620542
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
    Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
    Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of Donor Specific HLA Antibody Monitoring After Kidney Transplantation.
    Rao S; Ghanta M; Lee IJ; Gillespie A; Parekh HK; Geier SS; Zeng X; Karachristos A; Lau KN; Karhadkar S; Di Carlo A; Sifontis NM; Constantinescu S
    Clin Transpl; 2014; ():143-51. PubMed ID: 26281139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical relevance of the de novo production of anti-HLA antibodies following intestinal and multivisceral transplantation.
    Gerlach UA; Lachmann N; Sawitzki B; Arsenic R; Neuhaus P; Schoenemann C; Pascher A
    Transpl Int; 2014 Mar; 27(3):280-9. PubMed ID: 24279605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation.
    Safavi S; Robinson DR; Soresi S; Carby M; Smith JD
    J Heart Lung Transplant; 2014 Dec; 33(12):1273-81. PubMed ID: 25130554
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Single fixed low-dose rituximab as induction therapy suppresses de novo donor-specific anti-HLA antibody production in ABO compatible living kidney transplant recipients.
    Tomita Y; Iwadoh K; Ogawa Y; Miki K; Kato Y; Kai K; Sannomiya A; Koyama I; Kitajima K; Nakajima I; Fuchinoue S
    PLoS One; 2019; 14(10):e0224203. PubMed ID: 31644555
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Differential Treatment Effects for Renal Transplant Recipients With DSA-Positive or DSA-Negative Antibody-Mediated Rejection.
    Koslik MA; Friebus-Kardash J; Heinemann FM; Kribben A; Bräsen JH; Eisenberger U
    Front Med (Lausanne); 2022; 9():816555. PubMed ID: 35174191
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intravenous immunoglobulin therapy in kidney transplant recipients with de novo DSA: Results of an observational study.
    Matignon M; Pilon C; Commereuc M; Grondin C; Leibler C; Kofman T; Audard V; Cohen J; Canoui-Poitrine F; Grimbert P
    PLoS One; 2017; 12(6):e0178572. PubMed ID: 28654684
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.